header logo image


Page 315«..1020..314315316317..320330..»

Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 with COVID-19 After Effects Growth Drivers, Top Key Players, Industry Segments and Forecast…

October 31st, 2020 5:53 pm

The research document entitled Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 by Company, Type and Application, Forecast to 2025 by MarketsandResearch.biz covers a host of metrics like supply-demand ratio, market frequency, market trends, dominant players of market driving factors, challenges, future prospects contains a forecast of 2020 and ending 2025. The report reveals the key elements influencing the market, the constraints, and the difficulties that could stop the market development. The report focuses on defining, describing, and analyzing the market competition landscape, market share, and development plans in future years. It sheds light on the key segments expected to dominate the market such as product type, application, and regions.

Market Dynamics:

The report explains an evaluation of the restraints, drivers and presents room for strategic planning. Factors that overshadow the global Induced Pluripotent Stem Cells (iPSCs) market growth are pivotal as they can be understood to compose different bends for getting hold of profitable opportunities. The regional segmentation has been analyzed in terms of business opportunities, demand & supply, and revenue generation potential. It also encompasses the analysis of the technical barriers, other issues, and cost-effectiveness affecting the market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/117651

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Then our industry analysts project the supply chains, market share, growth opportunities, market sizing, cost, applications, technologies, import & export, companies. The report provides a detailed overview of the supplier landscape, combative analysis, and key market strategies to gain a global Induced Pluripotent Stem Cells (iPSCs) market outlook, market trend, market forecast, market demand, market sales & price on competing companies. The region and segment that is expected to witness the fastest growth as well as to dominate the market has been indicated in the report. This research report recognizes the industrial base, productivity, manufacturers, strengths, recent trends, features.

Key players profiled in the global Induced Pluripotent Stem Cells (iPSCs) market include: Fujifilm Holding Corporation (CDI), ReproCELL, Astellas Pharma Inc, Ncardia, Cell Inspire Biotechnology, Sumitomo Dainippon Pharma, Pluricell Biotech, Fate Therapeutics, Inc

In market segmentation by types, the report covers: Human iPSCs, Mouse iPSCs

In market segmentation by applications, the report covers the following uses: Academic Research, Drug Development and Discovery, Toxicity Screening, Regenerative Medicine, Others

The report explores Induced Pluripotent Stem Cells (iPSCs) business policies, trading, market channels, market volume, providers of raw material and customer data, demand & supply ratio. Apart from that, geographic division relies on North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa).

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/117651/global-induced-pluripotent-stem-cells-ipscs-market-2020-by-company-type-and-application-forecast-to-2025

Main Market Perceptions Consist of The Following:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Read the original:
Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 with COVID-19 After Effects Growth Drivers, Top Key Players, Industry Segments and Forecast...

Read More...

Canine Stem Cell Therapy Market Overview, Development by Companies and Comparative Analysis by 2026 – The Think Curiouser

October 31st, 2020 5:53 pm

Global AllTheResearch offers the latest published report on Canine Stem Cell Therapy Market Analysis and Forecast 2019-2026 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the Canine Stem Cell Therapy Industry Key players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next 5 years.

The reports cover key developments in the Canine Stem Cell Therapy market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnerships & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from the Canine Stem Cell Therapy market are anticipated to lucrative growth opportunities in the future with the rising demand for Canine Stem Cell Therapy market in the global market.

The global Canine Stem Cell Therapy market was valued at US$ 118.5 Mn in 2018 and is expected to reach US$240.7 Mn in 2026, growing at a CAGR of 9.3% during the forecast period.

Request for a sample copy of the report to get extensive insights into Canine Stem Cell Therapy market @https://www.alltheresearch.com/sample-request/206

Key Players Covered in this Report

Canine Stem Cell Therapy Market Analysis by Segmentation Type, Application and Region.

By Type:

By Application:

Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the Canine Stem Cell Therapy Market is in important countries (regions), including United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia, etc. It also throws light on the progress of key regional Exchangeable Tip Drills such as North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Get COVID19 Impact Analysis & post-COVID19 opportunities in Canine Stem Cell Therapy Market @ https://www.alltheresearch.com/impactC19-request/206

Key Benefits research studies provide:

Information given in the research report pertains to different technological advancements introduced in recent years, which allows for a meticulous analysis of the Canine Stem Cell Therapy industry and offers a more comprehensive understanding to the readers. These advancements will help companies to gain a decisive advantage in the competitive landscape of the market. Companies are also adopting diverse strategies to stay ahead of their competitors. These strategies include mergers and acquisitions, partnerships, collaborations, and new product developments, among others.

The information has been gathered through primary and secondary sources, comprising of interviews from several industry experts and professionals. Secondary sources such as press releases, information from recognized institutes, and other collaterals have been utilized to holistically analyze the Canine Stem Cell Therapy industry. Further, top-down, and bottom-up approaches have also been employed to ensure 360-degree assessment.

Ask for more details or request custom reports from our industry experts @https://www.alltheresearch.com/customization/206

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference. While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: RohanEmail:[emailprotected]Phone: 1-888-691

See more here:
Canine Stem Cell Therapy Market Overview, Development by Companies and Comparative Analysis by 2026 - The Think Curiouser

Read More...

Global Adipose Derived Stem Cell Therapy Market 2020 Leading Players, Industry Updates, Comprehensive Analysis and Forecast 2025 – re:Jerusalem

October 31st, 2020 5:53 pm

MarketsandResearch.biz has published the latest market research study on Global Adipose Derived Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 combines market essential details, definitions, categorization, professional market study, and analysis of significant features. The report estimates the global Adipose Derived Stem Cell Therapy market share, competition landscape, market share, growth rate, future trends. The report presents an introduction and structure of the market where the worldwide markets vital regional market demands are studied. Exhaustive investigation about current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market has been given. The market report is segmented by, trends, latest analytics, top players, application usage, and various important geographical dividends.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/89396

Market Potential:

The report examines the performance of the market, comprehensive judgment of market state, ongoing trends, and finally the global competitive landscape. Major market vendors study has been forecasted to obtain the latest opportunities as there has been an increased emphasis on spending more on the work of research and development by many of the manufacturing companies. The global Adipose Derived Stem Cell Therapy market has gone through speedy business transformation by good customer relationships and competitive growth, significant changes within the market, and technological advancement in this market.

Moreover, the global Adipose Derived Stem Cell Therapy market report has analyzed sales, suppliers, advanced technology, production, the variable cost, types, sales, and market share for the approximate time from 2020 to 2025. The basic information, as well as the profiles, applications, and specifications of products market performance along with business overview, are offered. The report provides a detailed overview of the combative analysis, market trend, market size & share, market forecast, market demand, market sales & price on competing companies.

Key strategic manufacturers included in this report: AlloCure, Mesoblast, Cellleris, Antria, Intrexon, Celgene Corporation, Tissue Genesis, Cytori Therapeutics, Corestem, Pluristem Therapeutics, Cyagen, BioRestorative Therapies, Lonza, Pluristem Therapeutics, Celltex Therapeutics Corporation, iXCells Biotechnologies

The market can be segmented into product types as: Autologous Stem Cells, Allogeneic Stem Cells

The market can be segmented into applications as: Therapeutic Application, Research Application

Geographically, this document is segmented into different chief territories, containing profits, sales, growth rate, and market share (percent) in the areas listed below: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/89396/global-adipose-derived-stem-cell-therapy-market-2020-by-company-type-and-application-forecast-to-2025

On the basis of region, the global Adipose Derived Stem Cell Therapy is segmented into countries, with production, consumption, revenue (million USD), and market share and growth rate in these regions, from 2015 to 2025 (forecast). It contains the market data and forecasts, which is the most valuable component of market research studies and provides our clientele with the greatest competitive edge with top-level quality standards.

Reasons For Buying Market Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Follow this link:
Global Adipose Derived Stem Cell Therapy Market 2020 Leading Players, Industry Updates, Comprehensive Analysis and Forecast 2025 - re:Jerusalem

Read More...

Outlook on the Regenerative Medicine Global Market to 2025 – Impact of COVID-19 on the Market – GlobeNewswire

October 31st, 2020 5:53 pm

Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market grew at a CAGR of around 16% during 2014-2019. Regenerative medicine refers to a branch of biomedical sciences aimed at restoring the structure and function of damaged tissues and organs. It involves the utilization of stem cells that are developed in laboratories and further implanted safely into the body for the regeneration of damaged bones, cartilage, blood vessels and organs. Cellular and acellular regenerative medicines are commonly used in various clinical therapeutic procedures, including cell, immunomodulation and tissue engineering therapies. They hold potential for the effective treatment of various chronic diseases, such as Alzheimer's, Parkinson's and cardiovascular disorders (CVDs), osteoporosis and spinal cord injuries.

The increasing prevalence of chronic medical ailments and genetic disorders across the globe is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is prone to various musculoskeletal, phonological, dermatological and cardiological disorders, is stimulating the market growth. In line with this, widespread adoption of organ transplantation is also contributing to the market growth. Regenerative medicine minimizes the risk of organ rejection by the body post-transplant and enhances the recovery speed of the patient.

Additionally, various technological advancements in cell-based therapies, such as the development of 3D bioprinting techniques and the adoption of artificial intelligence (AI) in the production of regenerative medicines, are acting as other growth-inducing factors. These advancements also aid in conducting efficient dermatological grafting procedures to treat chronic burns, bone defects and wounds on the skin. Other factors, including extensive research and development (R&D) activities in the field of medical sciences, along with improving healthcare infrastructure, are anticipated to drive the market further. Looking forward, the publisher expects the global regenerative medicine market to continue its strong growth during the next five years.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global regenerative medicine market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, type, application and end user.

Breakup by Type:

Breakup by Application:

Breakup by End User:

Breakup by Region:

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Allergan PLC (AbbVie Inc.), Amgen Inc., Baxter International Inc., BD (Becton, Dickinson and Company), Integra Lifesciences Holdings Corporation, Medtronic plc, Mimedx Group Inc., Novartis AG, Osiris Therapeutics Inc. (Smith & Nephew plc) and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology 2.1 Objectives of the Study2.2 Stakeholders2.3 Data Sources2.3.1 Primary Sources2.3.2 Secondary Sources2.4 Market Estimation2.4.1 Bottom-Up Approach2.4.2 Top-Down Approach2.5 Forecasting Methodology

3 Executive Summary

4 Introduction4.1 Overview4.2 Key Industry Trends

5 Global Regenerative Medicine Market5.1 Market Overview5.2 Market Performance5.3 Impact of COVID-195.4 Market Forecast

6 Market Breakup by Type6.1 Stem Cell Therapy6.1.1 Market Trends6.1.2 Market Forecast6.2 Biomaterial6.2.1 Market Trends6.2.2 Market Forecast6.3 Tissue Engineering6.3.1 Market Trends6.3.2 Market Forecast6.4 Others6.4.1 Market Trends6.4.2 Market Forecast

7 Market Breakup by Application7.1 Bone Graft Substitutes7.1.1 Market Trends7.1.2 Market Forecast7.2 Osteoarticular Diseases7.2.1 Market Trends7.2.2 Market Forecast7.3 Dermatology7.3.1 Market Trends7.3.2 Market Forecast7.4 Cardiovascular7.4.1 Market Trends7.4.2 Market Forecast7.5 Central Nervous System7.5.1 Market Trends7.5.2 Market Forecast7.6 Others7.6.1 Market Trends7.6.2 Market Forecast

8 Market Breakup by End User8.1 Hospitals8.1.1 Market Trends8.1.2 Market Forecast8.2 Specialty Clinics8.2.1 Market Trends8.2.2 Market Forecast8.3 Others8.3.1 Market Trends8.3.2 Market Forecast

9 Market Breakup by Region9.1 North America9.1.1 United States9.1.1.1 Market Trends9.1.1.2 Market Forecast9.1.2 Canada9.1.2.1 Market Trends9.1.2.2 Market Forecast9.2 Asia Pacific9.2.1 China9.2.1.1 Market Trends9.2.1.2 Market Forecast9.2.2 Japan9.2.2.1 Market Trends9.2.2.2 Market Forecast9.2.3 India9.2.3.1 Market Trends9.2.3.2 Market Forecast9.2.4 South Korea9.2.4.1 Market Trends9.2.4.2 Market Forecast9.2.5 Australia9.2.5.1 Market Trends9.2.5.2 Market Forecast9.2.6 Indonesia9.2.6.1 Market Trends9.2.6.2 Market Forecast9.2.7 Others9.2.7.1 Market Trends9.2.7.2 Market Forecast9.3 Europe9.3.1 Germany9.3.1.1 Market Trends9.3.1.2 Market Forecast9.3.2 France9.3.2.1 Market Trends9.3.2.2 Market Forecast9.3.3 United Kingdom9.3.3.1 Market Trends9.3.3.2 Market Forecast9.3.4 Italy9.3.4.1 Market Trends9.3.4.2 Market Forecast9.3.5 Spain9.3.5.1 Market Trends9.3.5.2 Market Forecast9.3.6 Russia9.3.6.1 Market Trends9.3.6.2 Market Forecast9.3.7 Others9.3.7.1 Market Trends9.3.7.2 Market Forecast9.4 Latin America9.4.1 Brazil9.4.1.1 Market Trends9.4.1.2 Market Forecast9.4.2 Mexico9.4.2.1 Market Trends9.4.2.2 Market Forecast9.4.3 Others9.4.3.1 Market Trends9.4.3.2 Market Forecast9.5 Middle East and Africa9.5.1 Market Trends9.5.2 Market Breakup by Country9.5.3 Market Forecast

10 SWOT Analysis10.1 Overview10.2 Strengths10.3 Weaknesses10.4 Opportunities10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis12.1 Overview12.2 Bargaining Power of Buyers12.3 Bargaining Power of Suppliers12.4 Degree of Competition12.5 Threat of New Entrants12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape14.1 Market Structure14.2 Key Players14.3 Profiles of Key Players14.3.1 Allergan PLC (AbbVie Inc.)14.3.1.1 Company Overview14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis14.3.2 Amgen Inc.14.3.2.1 Company Overview14.3.2.2 Product Portfolio14.3.2.3 Financials 14.3.2.4 SWOT Analysis14.3.3 Baxter International Inc.14.3.3.1 Company Overview14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis14.3.4 BD (Becton, Dickinson and Company)14.3.4.1 Company Overview14.3.4.2 Product Portfolio 14.3.4.3 Financials 14.3.4.4 SWOT Analysis14.3.5 Integra Lifesciences Holdings Corporation14.3.5.1 Company Overview14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis14.3.6 Medtronic Plc14.3.6.1 Company Overview14.3.6.2 Product Portfolio 14.3.6.3 Financials14.3.6.4 SWOT Analysis14.3.7 Mimedx Group Inc.14.3.7.1 Company Overview14.3.7.2 Product Portfolio14.3.7.3 Financials 14.3.8 Novartis AG14.3.8.1 Company Overview14.3.8.2 Product Portfolio 14.3.8.3 Financials14.3.8.4 SWOT Analysis14.3.9 Osiris Therapeutics Inc. (Smith & Nephew plc)14.3.9.1 Company Overview14.3.9.2 Product Portfolio14.3.10 Thermo Fisher Scientific Inc.14.3.10.1 Company Overview14.3.10.2 Product Portfolio 14.3.10.3 Financials14.3.10.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/ywnlq5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Link:
Outlook on the Regenerative Medicine Global Market to 2025 - Impact of COVID-19 on the Market - GlobeNewswire

Read More...

Rising Adoption of Cell Therapy Processing Market by 2020-2027 with Major Giants: BioTime, Inc., Regeneus Ltd., Targazyme, Inc., Bone Therapeutics,…

October 31st, 2020 5:53 pm

The Cell Therapy Processing market was valued at $1,695 million in 2018, and is projected to reach $12,062 million by 2027, registering a CAGR of +27% from 2020 to 2027.

The Global Cell Therapy Processing Market provides a comprehensive outlook of the Global Market globally. This report gives a thorough examination of the market and, provides the market size and CAGR value for the forecast period 2020-2027, taking into account the past year as the base year.

Cell therapy processing refers to the administration of living cells in a patients body for treating a disease. For cell processing therapy, different types of cells can be utilized, including neural cells, skeletal muscle cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal cells. Moreover, it is used for the treatment of cancers, repairmen of spinal cord injuries, infectious & urinary diseases, autoimmune diseases, improvement of a weakened immune system, rebuilding damaged cartilage in joints, and helping patients with neurological disorders.

Get up to 60% Discount on this report @: https://www.reportconsultant.com/ask_for_discount.php?id=76930

The Cell Therapy Processing Market Analysis Report includes Top Companies:

BioTime, Inc., Regeneus Ltd., Targazyme, Inc., Bone Therapeutics, NeuroGeneration, and Invitrx Therapeutics, Inc.

This report segments the Global Cell Therapy Processing Market on the basis of Types are:

On The basis Of Application, the Global Cell Therapy Processing Market is segmented into:

Regional Analysis For Cell Therapy Processing Market:

Try a sample Copy of this report now! @

https://www.reportconsultant.com/request_sample.php?id=76930

The research report provides in-depth analysis on:

In this study, the years considered estimating the market size of Cell Therapy Processing are as follows:

History Year: 2014-2018

Base Year: 2018

Estimated Year: 2019

Forecast Year 2020 to 2027

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Content:-

Chapter 1 Global Cell Therapy Processing Market Overview

Chapter 2 Market Data Analysis

Chapter 3 Market Technical Data Analysis

Chapter 4 Market Government Policy and News

Chapter 5 Market Productions Supply Sales Demand Market Status and Forecast

Chapter 6 Global Market Manufacturing Process and Cost Structure

Chapter 7 Global Cell Therapy Processing Market Key Manufacturers

Chapter 8 Up and Down Stream Industry Analysis

Chapter 9 Marketing Strategy Market y Analysis

Chapter 10 Market Development Trend Analysis

Chapter 11 Global Global Cell Therapy Processing Market New Project Investment Feasibility Analysis

About us:

Report Consultant is a prime destination for your business aptitude and analytical solutions because we provide qualitative and quantitative sources of information that are proficient to give one-stop solutions. We skillfully syndicate qualitative and quantitative research in exact proportions to have the best report, which not only gives the most recent insights but also assists you to grow.

Contact us:

Rebecca Parker

(Report Consultant)

Contact No: +81-368444299

sales@reportconsultant.com

http://www.reportconsultant.com

Read this article:
Rising Adoption of Cell Therapy Processing Market by 2020-2027 with Major Giants: BioTime, Inc., Regeneus Ltd., Targazyme, Inc., Bone Therapeutics,...

Read More...

Cancer Stem Cells (CSCs) Market to Flourish with an Impressive Cagr During 2020-2027 – The Think Curiouser

October 31st, 2020 5:53 pm

Cancer Stem Cells (CSCs) Latest Research Report 2020 2026 covers a complete market structure across the world with the detailed industry analysis of major key factors. This report provides strategic recommendations consulted by the industrial experts including market forecasts, profit, supply, raw materials, labour cost, manufacturing expenses, proportion of manufacturing cost structure, latest market trends, demands and much more.

The progress in different sectors of the market that are highly dependent on market characteristics, industry chain, and market dynamics are also appearing in higher demand for the Cancer Stem Cells (CSCs) . Due to the increase of new technologies, the Cancer Stem Cells (CSCs) has been assisted in the development of the industry.

Request Sample Report @ https://chronicalmarketresearch.com/request-for-sample-report/25206

Key Players:

The Key manufacturers that are operating in the global Cancer Stem Cells (CSCs) market are:

Janssen

Qiagen

Advanced Cell Diagnostics

ApoCell

Biofluidica

Clearbridge Biomedics

CytoTrack

Celsee

Fluxion

Gilupi

Cynvenio

On-chip

YZY Bio

BioView

Creatv MicroTech

Fluidigm

Ikonisys

AdnaGen

IVDiagnostics

Miltenyi Biotec

Aviva Biosciences Corporation

ScreenCell

Silicon Biosystems

Competitive Landscape

The competition section of the Grapefruit report supplies exhaustive analysis of the competitive landscape in the business along with a product portfolio matrix. The section involves information on leading manufacturers which provide an insight into their financial performance, business highlights, and future plans. Furthermore, the Cancer Stem Cells (CSCs) report is classified according to their type, application, and regions by geography.

Request Discount About This Report @ https://chronicalmarketresearch.com/discount-request-on-report/25206

Continuous Cancer Stem Cells (CSCs) Research Market report will be beneficial for:

Global Cancer Stem Cells (CSCs) Region Coverage (Regional Output, Demand & Forecast by Countries etc.): North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia, Spain and Benelux) Asia Pacific(China, Japan, India, Southeast Asia and Australia), Latin America (Brazil, Argentina and Colombia) Middle East and Africa.

Following are the segments covered by the report are:

CellSearch

Others

By Application:

Breast Cancer Diagnosis and Treatment

Prostate Cancer Diagnosis and Treatment

Colorectal Cancer Diagnosis and Treatment

Lung Cancer Diagnosis and Treatment

Other Cancers Diagnosis and Treatment

Request For Customization About This Report @ https://chronicalmarketresearch.com/request-for-customization/25206

Reasons to Buy of Cancer Stem Cells (CSCs) Report

* Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

* Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.

* Understand and respond to your competitors business structure and strategies with detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities, and threats are analyzed, providing you with an up to date objective view of the company.

* Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services, and business strategy.

In the end, This report additionally presents product specification, producing method, and products cost structure. Production is separated by regions, technology and applications. The Cancer Stem Cells (CSCs) report includes investment come analysis, and development trend analysis. The key rising opportunities of the fastest growing international Grapefruit industry segments are coated throughout this report.

Contact Us

Chronical Market Research,

4004 W Lake Sammamish,

Pkway B9 Redmond,

WA 98052 United States.

Tel: +44 115 888 3028

Web: http://www.chronicalmarketresearch.com

About Us

At Chronical Market Research, we understand that the research we provide is only as good as the outcome it inspires. These reports are generated by well-renowned publishers on the basis of the data acquired from an extensive research and credible business statistics. Thats why we are proud to provide the widest range of research products, multilingual 24/7 customer support and dedicated custom research services to deliver the insights you need to achieve your goals. Take a look at few of our aspects that makes Chronical Market Research an asset to your business.

Read more:
Cancer Stem Cells (CSCs) Market to Flourish with an Impressive Cagr During 2020-2027 - The Think Curiouser

Read More...

Stem Cell Cryopreservation Equipment Market : In-depth Analysis to Understand the Competitive Outlook of the Global Industry with Future Estimations -…

October 31st, 2020 5:53 pm

The research report focuses on target groups of customers to help players to effectively market their products and achieve strong sales in the global Stem Cell Cryopreservation Equipment Market. It segregates useful and relevant market information as per the business needs of players. Readers are provided with validated and revalidated market forecast figures such as CAGR, Stem Cell Cryopreservation Equipment market revenue, production, consumption, and market share. Our accurate market data equips players to plan powerful strategies ahead of time. The Stem Cell Cryopreservation Equipment report offers deep geographical analysis where key regional and country level markets are brought to light. The vendor landscape is also analysed in depth to reveal current and future market challenges and Stem Cell Cryopreservation Equipment business tactics adopted by leading companies to tackle them.

Market dynamics including drivers, restraints, Stem Cell Cryopreservation Equipment market challenges, opportunities, influence factors, and trends are especially focused upon to give a clear understanding of the global Stem Cell Cryopreservation Equipment market. The research study includes segmental analysis where important type, application, and regional segments are studied in quite some detail. It also includes Stem Cell Cryopreservation Equipment market channel, distributor, and customer analysis, manufacturing cost analysis, company profiles, market analysis by application, production, revenue, and price trend analysis by type, production and consumption analysis by region, and various other market studies. Our researchers have used top-of-the-line primary and secondary research techniques to prepare the Stem Cell Cryopreservation Equipment report.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2797897&source=atm

Our impartial and unbiased approach toward Stem Cell Cryopreservation Equipment market research is one of the major benefits offered with this research study. While internal analysis holds great importance in market research, secondary research helps guide changes during the preparation of a Stem Cell Cryopreservation Equipment research report. We dont simply take the word of third parties, we always look for justification and validation before using their data or information in our research study. We have attempted to give a holistic view of the global Stem Cell Cryopreservation Equipment market and benchmark almost all important players of the industry, not just the prominent ones. As we focus on the realities of the global Stem Cell Cryopreservation Equipment market, be rest assured that you are on the right path to receiving the right information and accurate data.

Segment by Type, the Stem Cell Cryopreservation Equipment market is segmented intoLiquid PhaseVapor Phase

Segment by Application, the Stem Cell Cryopreservation Equipment market is segmented intoCord Blood Stem Cell CryopreservationOther Stem Cell Cryopreservation

Regional and Country-level AnalysisThe Stem Cell Cryopreservation Equipment market is analysed and market size information is provided by regions (countries).The key regions covered in the Stem Cell Cryopreservation Equipment market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

Key players of the global Stem Cell Cryopreservation Equipment market are profiled on the basis of various factors, which include recent developments, business strategies, financial strength, weaknesses, and main business. The Stem Cell Cryopreservation Equipment report offers a special assessment of top strategic moves of leading players such as merger and acquisition, collaboration, new product launch, and partnership.

Competitive Landscape and Stem Cell Cryopreservation Equipment Market Share AnalysisStem Cell Cryopreservation Equipment market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Stem Cell Cryopreservation Equipment business, the date to enter into the Stem Cell Cryopreservation Equipment market, Stem Cell Cryopreservation Equipment product introduction, recent developments, etc.The major vendors covered:ChartWorthington IndustriesCesca TherapeuticsShengjie Cryogenic EquipmentSichuan Mountain VerticalQingdao Beol

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2797897&source=atm

Our objective data will help you to make informed decisions related to your business. The powerful insights provided in the Stem Cell Cryopreservation Equipment report will lead to better decision-making and deliverance of actionable ideas. The information that this research study offers will assist your business to the position in the best manner possible for driving Stem Cell Cryopreservation Equipment market growth and gain sound understanding about issues affecting the industry and the competitive landscape. Players can actually improve their reputation and standing in the global Stem Cell Cryopreservation Equipment market as they develop improved business strategies and gain more confidence with the help of the research study.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2797897&licType=S&source=atm

Table of Contents

Market Overview: In this section, the authors of the report provide an overview of products offered in the global Stem Cell Cryopreservation Equipment market, market scope, consumption comparison by application, production growth rate comparison by type, highlights of geographical analysis in Stem Cell Cryopreservation Equipment market, and a glimpse of market sizing forecast.

Manufacturing Cost Analysis: It includes manufacturing cost structure analysis, key raw material analysis, Stem Cell Cryopreservation Equipment industrial chain analysis, and manufacturing process analysis.

Company Profiling: Here, the analysts have profiled leading players of the global Stem Cell Cryopreservation Equipment market on the basis of different factors such as markets served, market share, gross margin, price, production, and revenue.

Analysis by Application: The Stem Cell Cryopreservation Equipment report sheds light on the consumption growth rate and consumption market share of all of the applications studied.

Stem Cell Cryopreservation Equipment Consumption by Region: Consumption of all regional markets studied in the Stem Cell Cryopreservation Equipment report is analysed here. The review period considered is 2014-2019.

Stem Cell Cryopreservation Equipment Production by Region: It includes gross margin, production, price, production growth rate, and revenue of all regional markets between 2014 and 2019.

Competition by Manufacturer: It includes production share, revenue share, and average price by manufacturers. Stem Cell Cryopreservation Equipment market analysts have also discussed the products, areas served, and production sites of manufacturers and current as well as future competitive situations and trends.

Contact Us:

ResearchMoz

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Read the original:
Stem Cell Cryopreservation Equipment Market : In-depth Analysis to Understand the Competitive Outlook of the Global Industry with Future Estimations -...

Read More...

Biologics Safety Testing Market : Segmentation, Industry Trends and Development to 2026 – Eurowire

October 31st, 2020 5:53 pm

According to Market Study Report, Biologics Safety Testing Market provides a comprehensive analysis of the Biologics Safety Testing Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry.

The Biologics Safety Testing Market is projected to reach USD XX Billion by 2023 from USD XX Billion in 2018, at a CAGR of XX%. This report spread across 122 Pages, Profiling 10 Companies and Supported with 114 Tables and 24 figures are now available in this research.

Request Sample Report @ https://beathanreports.com/request-for-sample-report/8407

The Biologics Safety Testing Market report is a compilation of first-hand information, qualitative and competitive assessment industry analysts, inputs from industry experts, and industry participants across the value chain. The research report market provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments, trending Key Factors, and geographies.

The following players are covered in this report:

Lonza Group

Charles River

Merck

SGS

WuXi AppTec

Thermo Fisher Scientific

Sartorius

Cytovance Biologics

Pace Analytical Services

Toxikon

Request Discount About This Report @ https://beathanreports.com/discount-request-on-report/8407

Growing popularity of soft adventure sports and increasing focus towards fitness are significant factors driving the growth of the Biologics Safety Testing market. However, high cost of Biologics Safety Testing might hinder the growth of the Biologics Safety Testing market. The demand for Biologics Safety Testing is high in North America and Europe region and the APAC is expected to grow at high CAGR which is creating lucrative business opportunities for the companies operating in the market.

MARKET SEGMENTATION

Breakdown Data by Type

Endotoxin Tests

Sterility Tests

Cell Line Authentication and Characterization Tests

Bioburden Tests

Cell Line Authentication

Residual Host Contaminant Detection Tests

Adventitious Agent Detection Tests

Others

Biologics Safety Testing Breakdown Data by Application

Vaccine Development

Blood Products Testing

Cellular & Gene Therapy

Tissue and Tissue-Related Products Testing

Stem Cell Research

Based on regional and country-level analysis, the Biologics Safety Testing market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Biologics Safety Testing market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

The following players are covered in this report:

Lonza Group

Charles River

Merck

SGS

WuXi AppTec

Thermo Fisher Scientific

Sartorius

Cytovance Biologics

Pace Analytical Services

Toxikon

Request For Customization About This Report @ https://beathanreports.com/request-for-customization/8407

This report provides a thorough analysis of the Biologics Safety Testing market through detailed research on a variety of topics to help players build strong growth strategies and strong presence in the industry. Readers will also be informed of the important sustainability strategies adopted by leading companies when operating in the Biologics Safety Testing market. The analyst also thoroughly evaluated the impact of these strategies on market growth and competition.

Chapter Details of Biologics Safety Testing Market:

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Biologics Safety Testing Market Landscape

Part 04: Biologics Safety Testing Market Sizing

Part 05: Biologics Safety Testing Market Segmentation by Type

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Reason to access this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall Biologics Safety Testing market and its sub segments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies.

Contact Us

Beathan Report,

4004 W Lake Sammamish,

Pkway B9 Redmond,

WA 98052 United States.

Tel: +44 115 888 3028

Web: http://www.beathanreports.com

About Us

Visit link:
Biologics Safety Testing Market : Segmentation, Industry Trends and Development to 2026 - Eurowire

Read More...

How Humanity Spent Its First 20 Years in Orbit Aboard the ISS – WIRED

October 31st, 2020 5:53 pm

A few years before, Congress had designated the US portion of the ISS as the newest addition to the countrys national laboratories, which would be responsible for handling all non-NASA microgravity research. In 2011, NASA officials selected the nonprofit Center for Advancement of Science in Space to manage the laboratory, which has been responsible for shepherding hundreds of experiments from researchers at American universities and companies. The lab collaborates with the National Science Foundation and the National Institutes of Health to select those experiments and flies about 50 every year.

We have this awesome model of a public-private partnership on this station that lends itself to organizations other than NASA who are doing things in microgravity that may not relate to space exploration, says Ken Shields, the chief operation officer of the ISS National Laboratory. In developing these partnerships, we now have companies that are able to do technology research and development on the station in a rapid way and apply the results.

The ISS National Lab handles experiments in both basic and applied science. Out of the hundreds of inquiries received every year, the lab can fly only a few dozen payloads that fall into a few broad categories of interest, such as remote sensing or life sciences. While an earthbound national lab like Lawrence Livermore or Argonne might have thousands of employees, the ISS National Lab has only a handful of NASA crew members. We are extremely reliant upon the astronauts to execute the experiments, says Michael Roberts, the acting chief scientist of the ISS National Laboratory. He says the limited time of the astronauts, who are also tasked with carrying out NASAs own experiments and taking care of the station, creates all sorts of unique challenges that arent faced by other national labs. Just getting the experiments into their hands is fraught with logistical difficulties. It's not an easy prospect to take an experiment, package it up, put it on a rocket, launch it to a remote destination, have it transferred over, have it activated, have it shut down, collected, and sent back, Roberts says.

A science or technology payload on the ISS could involve anything from creating fireballs to growing barley for beer, but NASA administrators have singled out a few core areas that they think are the most promising for R&D in low earth orbit. Manufacturing in microgravity, for instance, has advantages for making exotic materials like a fragile type of glass that could dramatically improve the performance of undersea cables. But arguably the most exciting applications are in the medical field; experiments with organs on a chip could eventually eradicate animal testing and expedite drug discovery. The microgravity environment could be harnessed to grow 3D cell-tissue models, called organoids, that will be useful for studying a variety of human diseases.

Last year, Valentina Fossati, a researcher at the New York Stem Cell Foundation, sent a few organoids to the ISS in order to study key cellular mechanisms in Parkinsons disease and multiple sclerosis in microgravity. Fossati is particularly interested in the role that microglia, nervous-system cells that are involved in the process of neuroinflammation, play in these diseases. Microglia are extremely sensitive to their environment, so studying how they behave in the absence of gravity is critical to getting a better understanding of their role in neurodegenerative diseases. Its really about disease modeling and trying to understand what is happening in the brain, says Fossati. What Im trying to re-create in a dish is how the neurons die. The absence of gravity would very likely change what happens between the cells. Although Fossatis research is ultimately about treating people on Earth, it could also help improve astronaut health by revealing the ways that long stays in microgravity affect our brain cells.

Read the original here:
How Humanity Spent Its First 20 Years in Orbit Aboard the ISS - WIRED

Read More...

What to Know in Washington: Provisional Ballots May Play Role – Bloomberg Government

October 31st, 2020 5:53 pm

If the U.S. is still waiting to learn who the president will be days or even weeks after Tuesdays election, provisional ballots are likely to be at the center of any disputes.

They are the ballots cast by voters whose eligibility is questioned for some reason. Those ballots are set aside and held for a period of days after the election while workers determine whether they should be counted.

Experts say the number of provisional ballots this year may set a record, exceeding the 2.7 million cast in 2012 and almost 2.5 million cast in 2016, in part because some voters who requested ballots by mail are showing up at polls to vote in person. That could lead to late results in key battleground states such as Pennsylvania where President Donald Trump won by only 44,292 votes in 2016 if the race is close and the source of challenges and litigation.

Its just another one of those things that plays into the unusual nature of this election, G. Terry Madonna, director of the Center for Politics and Public Affairs at Franklin and Marshall College in Pennsylvania, said of provisional ballots.

Provisional ballots have come into play in the past. Democrat John Kerry held off conceding the 2004 presidential race to Republican George W. Bush until the morning after the election because he waited until it was clear the 157,714 provisional ballots cast in Ohio couldnt change the outcome.

In 2016, Trump carried Arizona by 91,234 votes, and there were 102,510 provisional ballots, according to the U.S. Election Assistance Commission. Pennsylvania had 26,451 provisionals, and that was before the commonwealth expanded voting by mail last year.

Greater use of mailed ballots, coupled with disruptions in mail service, may contribute to the bumper crop of provisional ballots. After initially urging voters to request mail-in ballots in response to the pandemic, Democratic leaders have been telling people to vote in person or deliver the ballot to an elections office or an approved drop box to avoid the risk of it being disqualified on technical grounds or having its delivery delayed by the U.S. Postal Service. Read more from Mark Niquette.

Photographer: David Paul Morris/Bloomberg

Voters who requested mail-in ballots but opt to vote in person could lead to more provisional ballots.

USPS Cites Covid, Holiday for Record Delays: The U.S. Postal Service delivered 80.85% of first-class mail on time for the week ending Oct. 23, compared with previous weeks figure of 85.58%, according to a news release. The agency listed factors including high mail volume, Covid-19 impacts, the Oct. 12 federal holiday and ongoing efforts to prioritize ballots for the Nov. 3 election. The on-time rate is the lowest of the year, according to the Save the Post Office website that tracks the agency. Read more from Todd Shields.

BGOVs Downballot Races to WatchReddit AMA: Join Bloomberg Governments elections guru Greg Giroux this afternoon on Reddit for an AMA on the congressional elections, where hell take questions on the races to watch. Follow his AMA here at 2 p.m. today.

Biden Win Would Offer Path to Kill Pipeline: Days after taking office, Trump cleared the way for construction of an oil pipeline in the Midwest that had been the focus of months of opposition by climate activists, celebrities and Native Americans. Now opponents of the Dakota Access Pipeline are pressuring Joe Biden to take the extraordinary step of returning the favor should he win the White House. Analysts said they couldnt recall a president shutting down an operating pipeline before, which is why its being viewed as a litmus test of how far hed go to appease environmentalists who have supported him. Read more from Ari Natter.

Biden Pledges Not to Extort South Korea: Biden pledged not to use the threat of cutting U.S. troop levels in South Korea as a bargaining chip, after the Trump administration demanded Seoul pay far more for American protection. Biden said if he wins the U.S. election next week, he wont be extorting Seoul with reckless threats to remove our troops, according to a special contribution he made to South Koreas Yonhap News Agency published today. Read more from Jon Herskovitz.

Trumps China Scorecard Shows Many Defeats: Trump ran for office pledging to rewrite the U.S.s economic ties with Beijing, which he blamed for hollowing out Americas manufacturing base and impoverishing its workers. But his four years in the White House have shown limited impact on the metrics he laid out. U.S. companies cite much the same concernsand the same growth objectiveswith regard to China today as they did when Trump took office. The unprecedented trade war that Trump launched, breaking GOP free-trade orthodoxy along the way, has ended up costing American factory jobs, not creating them, economists claim. The state support for Chinese enterprises that Trump pledged to confront remains intact.

Trumps term has, however, had a notable impact on American attitudes toward China. In time, that could prove the dynamic that affects economic ties in ways the current president has struggled to achieve. And it underscores that Washingtons policy on China is forever changed, regardless of who wins next Tuesdays election. Read more from Jenny Leonard.

Health-Care on the Ballot in Several States: Big money is betting on health-care initiatives in California, Oregon, and Colorado where voters are being asked Nov. 3 to add taxes on vaping, mandate that doctors always be on site when dialysis centers are open, and approve $5.5 billion in bonds for the sole stem cell research funding agency in the country. Tens of millions of dollars are fueling arguments over what to fund and why because, essentially, people are more interested in health-care initiatives, said Arturo Vargas Bustamante, associate professor in the Department of Health Policy and Management at the University of California, Los Angeles. Read more from Joyce E. Cutler.

Gerrymander Power on the Line: A shift toward independent redistricting commissions helped spur national political parties to spend record cash in the hope of controlling the next congressional redistricting. The outcomes in just a few races in a few states will determine the Republican Partys chances of winning congressional majorities for the next decade. And were fighting like hell to win, Republican State Leadership Committee President Austin Chambers said in an email. His group raised $23 million in the third quarter and is targeting 115 districts that could hold the keys to a 136-seat swing in the U.S. House.

Democrats are fighting money with money. The Democratic Legislative Campaign Committee has pledged to spend $50 million in state races this cyclemore than six times what it spent in 2010. Read more from Alex Ebert.

Biden Courts Latino Voters as Tie-Breakers: Biden appealed to Hispanic voters in Florida, a closely divided battleground state where a win next week would give him the presidency. The heart and soul of the country is at stake right here in Florida. Its up to you. You hold the key. If Florida goes blue, its over, Biden said in a neighborhood in Broward County, which stretches south from Fort Lauderdale toward Miami and is a key source of Democratic votes in the state. Read more from Jennifer Epstein.

Facebook Says Technical Hiccups Improperly Blocked Campaign Ads: Facebook revealed yesterday how internal technical glitches disrupted the delivery of some ads from the Biden and Trump campaigns, but said it made changes to resolve those hiccups in the run-up to the November election. The social media giants admission followed complaints from the Biden camp about how thousands of its ads were blocked. Facebook said in a blog post it spotted unanticipated issues affecting both campaigns, including technical flaws that caused a number of ads to be paused improperly. Read more from Sarah Frier.

Trumps Social Media Order Defeats Legal Challenge: The Trump administration defeated a challenge by Rock the Vote and Voto Latino to a recent executive order targeting social media companies that fact-check the presidents posts about the election, when a federal judge said yesterday that the get-out-the-vote groups lacked standing to bring the case. Judge William H. Orrick said the groups couldnt show the order regulated Facebook, Twitter, or another social media website in any way or credibly threatened them with prosecution. Read more from Mike Leonard.

BGOV OnPoint: Section 230 Internet Shield Faces Bipartisan Attacks.

Zeta Disrupts Early Voting in Georgia: Hurricane Zeta caused disruptions to early voting across the South yesterday, including in the key battleground states of Georgia and North Carolina. Zeta, now a tropical storm, knocked out power to more than 1 million homes and businesses as early in-person voting enters a final stretch with five days to go until Election Day. Friday is Georgias last day to vote while voters in North Carolina have until Saturday. Read more from Misyrlena Egkolfopoulou and Joe Ryan.

More Hawaiians Voted Early Than All of 2016: Early voting in Hawaii has already surpassed the total number of ballots cast in the state in the 2016 election. Data from the U.S. Elections Project, which tracks early voting, found Hawaii has seen turnout hit 104.5% of its total from the last election. More than half of all registered voters in Hawaii have already sent in their ballots, topping the record for the total number of votes cast in the state for a general election. Read more from Emma Kinery.

U.S. Sets Daily Virus Case Record: New U.S. cases topped 86,000, setting a new daily record, as the outbreak intensifies ahead of next weeks presidential election. Read more from Bloomberg News.

U.S. Buying Gowns from Untested Makers: Several U.S. companies that won almost half a billion dollars in government contracts to make hospital gowns appear to have too few workers and not enough factory space to complete the job when the awards were made, according to a Bloomberg Law analysis. At least 11 contractors and subcontractors began making protective gear only after the pandemic began, according to press releases and news reports. Of the 15 primary contractors, eight had never received a federal contract prior to 2020, according to federal government contracting records. The Defense Department says contractors went through a rigorous process and met stringent criteria.

Still, members of Congress are raising questions. Some of those contracts have been to companies that have very little experience with producing that kind of equipment, that the standards have not always been up to par, and its created some real challenges, Sen. Jeanne Shaheen (D-N.H.) said during a Senate Armed Services committee hearing Oct 1. Read more from Shira Stein.

Covid Relief Laws May Bolster ACA Legal Case: Republicans may have hurt their own legal case against Obamacare by repeatedly expanding on and amending the signature health law since 2017, most recently in their response to the coronavirus pandemic. You cant build on the ACAs protections for the Covid bills if the act doesnt exist, said Abbe Gluck, a professor of law and the founding faculty director of the Solomon Center for Health Law and Policy at Yale Law School.

The U.S. Supreme Court will assess legal arguments on the constitutionality of the Affordable Care Act on Nov. 10. What Congress intended to do with the ACA is a central line of dispute in the high stakes case, and the pandemic has given supporters of the law a new opportunity to prove it was meant to stay. Read more from Lydia Wheeler.

New Projection Shows Higher Death Toll: The Institute for Health Metrics and Evaluation, an influential modeling group, is projecting a higher death toll in the U.S. amid the surge in Covid cases and hospitalizations. The group is now projecting about 405,000 deaths due to the virus by Feb. 1, representing a nearly 20,000 increase from a prior projection of 386,000. Europe is seeing a surge right now and Europe is ahead about a month from the United States, said Ali Mokdad, a professor of health metrics sciences with IHME. So basically we are watching what would unfold here in the United States. Read more.

CDC Evictions Moratorium Upheld by Judge: A federal judge ruled against landlord groups trying to block the U.S. Centers for Disease Control and Preventions national moratorium on evictions amid the coronavirus crisis. U.S. District Judge J.P. Boulee in Atlanta yesterday rejected a motion for a preliminary injunction brought by the New Civil Liberties Alliance and National Apartment Association, which represents some 85,000 landlords responsible for 10 million rental units. The judge said the public interest in curtailing the spread of Covid outweighed the landlords economic interest. Read more from Chris Dolmetsch.

Trump Rule Leads Contractors to Cut Training: Trumps recent attempt to curb corporate diversity training will linger even if he loses Tuesdays election to Biden. Already, federal contractors are unsure of what they can say about race. More than 300 events, training programs, research projects and other diversity-related activities have been delayed or canceled because of concern about a Sept. 22 executive order aimed at banning federal contractors and agencies from using terms in diversity training that the administration considers divisive and illegal, according to the African American Policy Forum, a social justice think tank. A Labor Department official said last week that the agencys already received more than 100 complaints via a government hotline to report possible violations. Read more from Paige Smith and Jeff Green.

Hackers Plan More Attacks on U.S. Hospitals: A Russia-based ransomware group responsible for a new wave of attacks against U.S. hospitals is laying the groundwork to cripple at least ten more, according to the cybersecurity firm Prevailion. Prevailions analysis comes a day after the FBI and two other federal agencies issued a warning about an imminent and credible threat to hospitals and health-care providers from cyberattacks, including ransomware capable of locking entire computer networks. The hacking group responsible has already hit at least nine hospitals in three weeks, crippling critical computer systems and demanding multimillion-dollar ransoms. Read more from Alyza Sebenius, William Turton and Michael Riley.

Insurers Must Post Out-of-Pocket Medical Costs: Health insurers will have to post on the internet personalized out-of-pocket costs to patients under a new rule finalized yesterday. Insurance plans will also be required to make their in-network negotiated rates with doctors and allowable out-of-network rates available to the public, according to the multiagency rule. They will be required to post their negotiated pharmaceutical prices and the historical net prices for all their covered drugs. Read more from Shira Stein, Lydia Wheeler and John Tozzi.

How the Google Case Could Play Out: Google and the Justice Department are set to face each other in court today for the first time since the government sued the company for illegally monopolizing internet search. The hearing marks the first time attorneys for Google and the government will come together to start mapping out the the litigation process. It will set the stage for whats shaping up to be a drawn-out court battle that could ultimately weaken Googles gatekeeper position over the web if the government is successful. Vicky Graham lays out how to follow the case as it winds its way through federal court.

737 Jet Crash Victims Demand U.S. Records: The relatives of the 157 people who died in the crash of a Boeing 737 Max in Ethiopia are demanding more records from U.S. safety agencies, according to a pair of letters sent on the second anniversary of another accident involving the plane. A letter to the National Transportation Safety Board, which assisted in the investigation of both crashes, accused it of an unreasonable pro-secrecy stance. Alan Levin has more.

Gray Wolf Protections Stripped, Stirring Lawsuit Threats: The Interior Department announced yesterday it will strip endangered species protections from the gray wolf. Environmental groups vowed to challenge the decision in court, saying it violates the Endangered Species Act by ignoring the best available science. If Democrat Joe Biden wins the presidency, his administration could seek to overturn the move. Todays action reflects the Trump administrations continued commitment to species conservation based on the parameters of the law and the best scientific and commercial data available, said Interior Secretary David Bernhardt. Stephen Lee and Kellie Lunney have more.

Administration Appeals Court Order on Visa Ban: The Trump administration is appealing a California federal courts Oct. 1 ruling that blocked the departments of State and Homeland Security from barring entry to the U.S. for certain temporary work visa holders. In their filing, U.S. Justice Department lawyers signaled theyll ask the San Francisco-based U.S. Court of Appeals for the Ninth Circuit to reinstate Trumps proclamation in full, Genevieve Douglas reports.

To contact the reporters on this story: Zachary Sherwood in Washington at zsherwood@bgov.com; Brandon Lee in Washington at blee@bgov.com

To contact the editors responsible for this story: Giuseppe Macri at gmacri@bgov.com; Loren Duggan at lduggan@bgov.com; Michaela Ross at mross@bgov.com

Read more from the original source:
What to Know in Washington: Provisional Ballots May Play Role - Bloomberg Government

Read More...

Impact of COVID-19 on Animal Cell Culture Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Life Technologies, Thermo Fisher,…

October 31st, 2020 5:53 pm

Animal Cell Culture Market research report is the new statistical data source added by A2Z Market Research.

Animal Cell Culture Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Animal Cell Culture Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=327288

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Life Technologies, Thermo Fisher, GE Healthcare, Corning (Cellgro), Takara, HiMedia, Atlanta Biologicals, PromoCell, Sigma-Aldrich, Zenbio, BD, Lonza, CellGenix, Merck Millipore

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Animal Cell Culture market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Animal Cell Culture markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=327288

Global Animal Cell Culture Market Segmentation:

Market Segmentation by Type:

Classical Media & SaltsSerum-free MediaStem Cell Media

Market Segmentation by Application:

Biopharmaceutical ManufacturingTissue Culture & EngineeringGene TherapyCytogenetic

Regions Covered in the Global Animal Cell Culture Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The report provides insights on the following pointers:

Table of Contents

Global Animal Cell Culture Market Research Report 2020 2026

Chapter 1 Animal Cell Culture Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Animal Cell Culture Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=327288

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Read the original:
Impact of COVID-19 on Animal Cell Culture Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Life Technologies, Thermo Fisher,...

Read More...

Lesaffre and Recombia Biosciences to advance innovative gene editing technology through a strategic partnership – PRNewswire

October 31st, 2020 5:52 pm

A strong commitment to innovationWith its partnership with Recombia, Lesaffre is investing in major pioneering technology. The ability to generate thousands of yeast strains in parallel, combined with laboratory automation, is expected to exponentially accelerate development of projects in the areas of health, the environment, and energy. The partnership also signifies Lesaffre's entry into the world of Synthetic Biology, considered to be the major biotechnological opportunity of this decade.

"This kind of partnership exemplifies an innovative way that industry can support and foster progress in Biotechnology. Through collaboration with scientists and entrepreneurs, we will be able to find new solutions, which will be beneficial for the future, especially in health or in environment protection," says Antoine Baule, Chief Executive Officer of Lesaffre.

An exclusive technologyRecombia Biosciences was founded by three Stanford University researchers in 2019 as a spin-off from the prestigious Stanford Genome Technology Center (SGTC).Recombia'stechnologies are based upon techniques that increase the efficiency of genome editing and enable engineering of yeast at very high throughput. The strategic collaboration with Lesaffre aims to advance Recombia's proprietary gene editing technologies to identify new yeast strains, discover novel yeast physiology of industrial relevance and optimize the production of biosourced ingredients and biofuels.

"We are excited to be working with Lesaffre on moving our gene editing programs forward," says Dr. Justin Smith, CEO of Recombia. "We see tremendous potential to leverage our expertise in genome editing and synthetic biology to develop new and innovative fermentation solutions and products."

Recombia is exclusively licensing four genome engineering technologies from Stanford University for their work.

"While precision genome editing has certainly advanced recently, there are still challenges, especially in making many genetic changes in parallel," said Dr.Bob St.Onge, COO and co-founder of Recombia Biosciences. "Recombia's technologies enable industrial yeast strain engineering by dramatically increasing the efficiency of high-throughput genome editing."

St.Onge and Smith co-founded the company with Professor Lars Steinmetz. The team has had a long working relationship at the SGTC.

"I am very excited to see the technologies we developed in academia applied in the industrial sector," said Steinmetz. "The Genome Technology Center has a long history of genomics technology development. I'm confident Recombia will continue in the tradition of the other successful companies that have spun out of the SGTC."

"The technology has broad utility and can be readily applied also to the development of non-genetically modified organisms,"says Carmen Arruda, Lesaffre R&I Manager. "With Recombia, Lesaffre can now explore a larger space of metabolic engineering hypotheses, develop prototype organisms at a faster pace, accelerate the design of appropriate selections and screenings of strains generated by classical breeding methods. We are excited to see what the future holds."

Working together to better nourish and protect the planetAs a global key player in the field of fermentation,Lesaffre is committed to continuing its investments in research and development to contribute to a safer, healthier and more natural world by developing the potential of micro-organisms, such as yeasts or beneficial bacteria.

More information about Recombia Biosciences at http://www.recombia.com

More information about Lesaffre at http://www.lesaffre.com

SOURCE Recombia Biosciences

Home

Read more:
Lesaffre and Recombia Biosciences to advance innovative gene editing technology through a strategic partnership - PRNewswire

Read More...

Integrity and Trust | Harvard Medical School – Harvard Medical School

October 31st, 2020 5:52 pm

Leaders from across academia, government and industry gathered to discuss regulatory science at the 2020 Global Conference on Regulatory Science. Top row, left to right: Peter Sorger, Amy Abernathy, George Daley, Norman Sharpless. Bottom row, left to right: Adam Palmer, Helga Gadarsdottir, Peter Mol, Steve Goodman.

Speakers and panelists from across academia, government and industry convened to discuss the future of the evaluation and regulation of new medicines at the first annual Global Conference on Regulatory Science, held virtually on Oct. 20 and 21.

While machine learning and data science were the conference themes, fundamental issues of integrity, transparency and patient trust were a refrain.

Get more HMS news here

The importance of these underlying issues has been starkly illuminated by the challenges posed by the COVID-19 pandemic, said Margaret Hamburg, former commissioner of the FDA and one of the events keynote speakers.

Even with all the best science, we can't generate the change we hope for if people don't trust it. Even a safe and effective vaccine won't help control the COVID-19 pandemic if people won't take it, said Hamburg.

For me, and I suspect or most of you, this is just enormously worrisome,"she added. "It's a powerful reminder that integrity and the trust it generates is such an essential foundation of everything else.

Scientific discoveries and technologies with the potential to transform human health emerge almost daily, and regulatory agencies like the FDA and its peers around the world have faced mounting challenges as they strive to keep up with the accelerating pace of innovationchallenges that have been amplified by the urgent need for therapeutics and vaccines for COVID-19.

Building trust among patients, balancing careful testing with timely approvals for potentially life-saving medicines, and other key topics were addressed over the course of the two-day conference, which was hosted by the Harvard-MIT Center for Regulatory Science (CRS), a partnership between Harvard University, MIT and the FDA that aims to further develop and improve the science of how drugs and other products are evaluated and brought to market.

Regulatory science is an increasingly compelling opportunity for fundamental innovation and real-world impact in creating safe and effective medicines, diagnostics and devices, said Peter Sorger, the Otto Krayer Professor of Systems Pharmacology at HMS.

Our goal is to try and improve these processes, make them more efficient, and critically, bring needed innovation to unmet medical needs, said Sorger, who co-directs the CRS with Florence Bourgeois, HMS associate professor of pediatrics at Boston Childrens Hospital, and Laura Maliszewski, executive director of the Harvard Program in Therapeutic Science and the Laboratory of Systems Pharmacology.

More than 650 attendees from around the world joined in the virtual discussions, which centered on the theme of how machine learning, data science and new technologiesincluding telemedicine and wearable devicesare changing drug development, clinical trials, medical care and more.

Speakers and panelists included Norman Sharpless, director of the National Cancer Institute; George Q. Daley, dean of HMS; Amy Abernathy, principle deputy commissioner of the FDA; and a broad range of leaders from academia, hospitals, government and industry.

The process of regulating new medicines and biotechnologies begins with scientists themselves, noted Daley.

Scientists bear the responsibility to participate in a shared governance model that invites transparent and independent oversight, he said, highlighting the Asilomar conference in 1975, when an international group of scientists came together to create voluntary guidelines for the manipulation of DNA, then a novel technology.

This established a precedent for self-regulation by scientists, which then informed subsequent regulation by government agencies.

The need for the scientific community to engage in self-governance has only increased in urgency, with the remarkably rapid emergence of CRISPR gene-editing approaches that can make permanent, heritable changes to an individuals DNA. At a meeting in 2015, Daley joined a cohort of scientists, including Jennifer Doudna, now a Nobel laureate, to strongly discourage germline genome editing.

We knew that this would have to be a prohibition that would be practiced by scientists and clinicians themselves, because the knowledge was emerging so rapidly it wasn't clear that the regulators were going to be ready to catch up, said Daley.

But in 2018, a rogue scientist illicitly edited the genomes of two embryos that were carried to term in China, sparking international controversy. If there is ever to be a possible safe and ethical path forward for emerging technologies such as germline editing, it must be paved by the open cooperation and collaboration of scientists, regulators, and importantly, the public, Daley said.

The payoff for this kind of cooperation can be enormous, and perhaps the best examples can be found in recent successes in the development and approval of new cancer medicines, said Sharpless.

I predict that 2020 will be the best year thus far for cancer drug approvals, said Sharpless. That progress has occurred during a time when the FDA has been besieged by a global pandemic.

A historic surge of new cancer medicines has entered the U.S. market in recent years, Sharpless added, a windfall that stems from decades of productive research on cancer biology and therapeutics.

An improved scientific understanding of cancer has led to the development of new medicines that have prompted new approaches to regulation by the FDA. Some cancer drugs demonstrate such efficacy in small-scale clinical trials, he noted, that it can become essentially unethical to withhold them while waiting for large phase III trials to finish.

This has been a change for the regulatory thinking of the FDA, and I would argue has been a change for the good of the patients, Sharpless said. It has made agents available to patients at a sooner date and led the pharmaceutical industry to develop cancer drugs knowing that they can get approval at an earlier stage.

The recent successes of cancer drugs are to be celebrated, but the question of how to replicate these successes in other diseases, such as neurodegeneration and other intractable diseases, remains a pressing concern, he said.

This question was discussed by conference speakers and panelists in many different contexts, particularly the potential of emerging technologies to reshape how clinical trials are conducted in the future.

A wealth of new technologies, from telemedicine to wearable devices, are allowing physicians and scientists to engage with patients in unprecedented ways. This could have a transformative impact in medicine in many ways, including by augmenting clinical trials, speakers said.

Such technologies could enable more frequent physician-patient interaction and the continuous monitoring of real-world data and evidenceproviding far more information than the intermittent site visits that most current trials use to collect data.

In addition, new technologies could help reduce disparities in access to clinical trials, panelists said, and allow for vastly improved patient recruitment, which would help ensure that new medicines are being evaluated on patients who have the best chance of benefiting.

If this potential is to be realized, patients must have confidence that their privacy and data are protected, said conference speakers and panelists.

In many ways, trust in data security and privacy are as important as any innovations in technology itself, panelists noted. This is a key issue for new digital medicine technologies and approaches, they added, and thoughtful and transparent regulation are critical.

Conference speakers also addressed a wide and diverse range of other issues, including how new technologies, such as artificial intelligence and digital pathology, are transforming clinical care and how large data sources like electronic medical records are linked and mined for insights into improving health.

The rapid growth of these and many other new technologies in health care present myriad complex issues for those tasked with evaluation and regulation, speakers and panelists said. And in many cases, as with genetic engineering, decision-making will require societal discourse.

As such, neutral forums to consider and debate new innovations, policies and regulationsone of the key functions of the CRS and its annual conferenceplay an increasingly important role in moving the complex discipline of regulatory science forward.

Central to this process is the ability to effectively collaborate around stakeholders, across academia, industry and regulatory agencies, said Bourgeois.

This is where the center comes in, serving as a platform to foster interdisciplinary and multi-stakeholder conversation, she said.

The remarkable discoveries and the acceleration and advances we are seeing in our understanding of diseases and how to treat themthese will most benefit patients if we have an efficient, rigorous and adaptable approach to the evaluation of the many rapidly emerging biotechnologies, Bourgeois said.

Continue reading here:
Integrity and Trust | Harvard Medical School - Harvard Medical School

Read More...

Gene-edited crops and animals: Best-kept secrets in the fight against climate change – Genetic Literacy Project

October 31st, 2020 5:52 pm

Advances in gene editing over the past decade have given scientists new tools to tailor the biochemistry of nearly any living thing with great precision. Because the biosphereincluding trees, crops, livestock, and every other organismsis a major source and sink for greenhouse gases (GHGs), these tools have profound implications for climate change. Gene editing is unlocking new ways to enhance natural and agricultural carbon sinks, limit emissions from agriculture and other major GHG-emitting sectors, and improve biofuels. Congress should act now to open this new frontier for climate innovation.

Gene editing uses enzymesCRISPR Cas9 is the most well-knownto identify, remove, and replace segments of an organisms DNA, much like using a word processor to edit a document. These tools originated as defense mechanisms so that bacteria could remove foreign DNA inserted by predatory viruses. Researchers have adapted this cellular machinery to introduce beneficial traits into plants and animals. The techniques are new, but they build on nearly a half century of experience with conventional genetic engineering and hundreds of millions of years of evolution.

Zooming out from the microscopic level, gene editing offers novel solutions to a diverse set of emissions-related problems.

The Trillion Trees initiative recognizes plants unique ability: using photosynthesis to capture carbon. Yet the process is surprisingly inefficient.Scientistshave moved swiftly to use their new toolkit to try to improve it, and several breakthroughs have already been reported. Further progress might enableproductivity gainsof 50 percent in major crops, slashing emissions radically, raising output per acre, and bolstering farmers incomes.

The decomposition and transport of wasted food accounts for the single largest portion of agricultural GHG emissions. Companies are already selling gene-editedsoybean oilwith a longer shelf life andpotatoesthat resist bruising, both of which reduce waste.

Next-generation biofuels from switchgrass, which grows easily on otherwise non-arable land, could power sustainable, low-carbon transport. The hitch has been that this plants key ingredient, cellulose, is hard to break down. Gene editing may open up this abundant resource by optimizing microbes that can efficiently process cellulose, yielding low-cost biofuels and spurring rural development.

The worlds 1.4 billion cattle account for about6 percentof global agriculture GHG emissions, in large part because of methane in their burps. Some cattle emit far less methane than others because of specific microbial populations in their digestive tracts. Gene editing could allow this trait to spread across herds,reducing emissions.

Gene editings enormous promise for solving societal problems, including climate change, has been slowed by concerns that it is neither natural nor safe. These concerns are misplaced. Humans have used breeding to shape the genomes of crops and livestock since the dawn of agriculture. Our new gene editing toolkit has been used by nature for hundreds of millions of years. Most important, in eleven major studies over the past four decades, the U.S. National Academy of Sciences hasfoundno new hazards in gene edited or genetically engineered products. Other authoritative bodies around the world have drawn the same conclusion, which has been confirmed by vast experience.

The urgency of the climate challenge is becoming clearer with each passing season as severe storms, droughts, fires, and other disasters become more frequent at home and around the world. Congress should take action today to accelerate gene-edited climate solutions. First, legislators should eliminate regulatory burdens that disincentivize innovation in gene-edited technologies and contribute little to human or environmental safety. Current regulations on gene-edited products have addedtens of millions of dollarsand multiple years to their development without delivering commensurate benefits for health, safety, or the environment.

Second, Congress should create a new agency to support agricultural research into high-reward biological technologies including gene editing. The ARPA-Terra Act of 2019 (S.2732) introduced by Sen. Michael Bennet would do so, emulating the highly successful models of the Defense Advanced Research Projects Agency (DARPA) and the Advanced Research Projects Agency-Energy (ARPA-E).

Finally, Congress should encourage innovative farmers to adopt new gene-edited crops and livestock to demonstrate their value and speed wider deployment. Existing tax credits for carbon capture could be expanded as these nascent products come to market.

Although gene editing is less than a decade old, it is already abundantly clear that it will be a powerful tool to address climate change. The science is ready and waiting for Congressional action.

See more here:
Gene-edited crops and animals: Best-kept secrets in the fight against climate change - Genetic Literacy Project

Read More...

ETFs in Focus on Bayer’s Bet on Gene Therapy – Yahoo Finance

October 31st, 2020 5:52 pm

Merger and acquisition activities have heated up in recent months and the niche spaces are in the limelight. After the telemedicine industry, gene therapy stocks jumped on the bandwagon. Gene therapy is a technique that uses genes to treat or prevent disease.

German drugmaker Bayer has made a big bet on gene therapy by announcing the acquisition of U.S. biotech firm Asklepios BioPharmaceutical for as much as $4 billion. The proposed acquisition will provide Bayer access to the adeno-associated virus (AAV) gene therapy platform and a pipeline led by clinical-phase treatments for Parkinsons, Pompe disease and congestive heart failure. Notably, AAV therapies offer improved efficacy, immune response, and tissue and organ specificity.

Additionally, the transaction will complements Bayers 2019 acquisition of BlueRock Therapeutics and advances its efforts to create platforms with the potential to have an impact on multiple therapeutic areas (read: Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers).

Under the terms of the deal, Bayer will pay an upfront consideration of $2 billion and potential success-based milestone payments of up to $ billion. About 75 % of the potential milestone-based contingent payments are expected to be due during the course of the next five years and the remaining amount thereafter.

The deal, pending regulatory approvals, is expected to close during the fourth quarter of 2020. Once the deal closes, Bayer will allow Asklepios, known as AskBio, to operate autonomously as part of a new cell and gene therapy unit in a bid to preserve its entrepreneurial culture. The cell and gene therapy unit will bundle Bayer's activities in this area moving forward in order to establish an innovation ecosystem for the participating partners, the German company said (see: all the Healthcare ETFs here).

The proposed deal will provide a boost to the gene therapy industry. Below, we have highlighted four ETFs that are expected to benefit from Bayers entrance into the gene therapy space:

ARK Genomic Revolution Multi-Sector ETF ARKG

This actively managed ETF is focused on companies that are likely to benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, and advancements in genomics into their business. With AUM of $2.9 billion, the fund holds 47 stocks in its basket and has 0.75% in expense ratio. It trades in an average daily volume of 978,000 shares (read: 4 Sector ETFs That Have Doubled This Year).

Invesco Dynamic Biotechnology & Genome ETF PBE

This fund follows the Dynamic Biotech & Genome Intellidex Index and provides exposure to companies engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. It holds 31 stocks in its basket and charges 57 bps in annual fees. The ETF has managed $229.9 million in its asset base while trades in a light volume of 6,000 shares per day. Expense ratio comes in at 0.57%. The product has a Zacks ETF Rank #3 (Hold) with a High risk outlook.

Global X Genomics & Biotechnology ETF GNOM

This product seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics and biotechnology. It follows the Solactive Genomics Index, holding 40 stocks in its basket. This ETF has accumulated $68 million in its asset base and charges 50 bps in annual fees. It trades in average daily volume of 31,000 shares (read: Why You Should Invest in Genomics ETFs).

iShares Genomics Immunology and Healthcare ETF IDNA

This ETF provides access to companies at the forefront of genomics and immunology innovation by tracking the NYSE FactSet Global Genomics and Immuno Biopharma Index. Holding 46 stocks in its basket, the fund has gathered $166.2 million in AUM and trades in moderate average daily volume of 58,000 shares. It charges 47 bps in annual fees.

Story continues

Zacks free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportInvesco Dynamic Biotechnology Genome ETF (PBE): ETF Research ReportsARK Genomic Revolution ETF (ARKG): ETF Research ReportsGlobal X Genomics Biotechnology ETF (GNOM): ETF Research ReportsiShares Genomics Immunology and Healthcare ETF (IDNA): ETF Research ReportsTo read this article on Zacks.com click here.Zacks Investment ResearchWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Read the original here:
ETFs in Focus on Bayer's Bet on Gene Therapy - Yahoo Finance

Read More...

Sugar beet industry flips narrative on GMO crops – Idaho State Journal

October 31st, 2020 5:52 pm

It's only been a few years since U.S. sugar beet farmers faced a potential financial crisis due to negative public perceptions about food products derived from biotechnology.

Nowadays, however, the sugar beet industry is flipping the narrative, capitalizing on what was once its Achilles heel its universal adoption of GMO seed.

Since, 2009, the nation's sugar beet crop has been almost entirely planted in seed genetically modified to resist glyphosate herbicide, which is produced at Bayer's Soda Springs plant. Lately, to strike a chord with an increasingly environmentally conscious consumer base, the sugar beet industry has been touting how biotechnology has made its crop production system far more sustainable.

Story continues below video

Idaho is the No. 2 state in production of sugar beets by ton.

"We have lots of data," said Scott Herndon, vice president and general counsel with the American Sugarbeet Growers Association. "We submitted something to the National Academy of Sciences where we identified 25 environmental gains achieved through biotech seeds related to water, soil and air."

Herndon explained the gene added to confer glyphosate resistance to GMO beets is entirely removed in the processing of sugar. He referenced laboratory testing conducted by his industry proving finished sugar raised by American sugar beet farmers is identical to organic sugar and cane sugar in general.

Yet efforts to pass GMO labeling laws prior to 2016 in states including Vermont, Washington State, Oregon and California resulted in conventional cane sugar enjoying a whopping price advantage of roughly 7 cents over beet sugar, said Luther Markwart, executive vice president of American Sugarbeet Growers Association.

"That's huge," Markwart said.

Furthermore, the large Pennsylvania-based candy manufacturer Hershey Co. removed GMO beet sugar from many of its products in 2015 in favor of conventional cane sugar. In explaining the decision, Hershey affirmed GMO ingredients are safe but emphasized its commitment to openness and transparency.

"People care about the food they eat," Hershey posted on its website. "They want to know what's inside and they want to have choices so that snack options meet their expectations."

Rather than providing the public with transparency, Markwart believes mandatory labeling of beet sugar would be misleading, causing people to falsely believe beet sugar and cane sugar are somehow different.

Under the Obama Congress passed a preemptive law in 2016 exempting beet-derived sugar from state GMO labeling requirements. It took effect in December of 2018, though food companies are still allowed to voluntarily state that a product is derived from a bioengineered crop.

"Once you got the federal preemption, all of a sudden the beet and cane price came back together," Herndon said.

Labeling proponents, however, note that surveys consistently find consumers support GMO labeling by wide margins, believing people who are skeptical of a technology that is found in more than three-quarters of the processed foods in supermarkets should have the ability to avoid it.

"While many in the scientific community assert that GMO foods are not toxic and are safe, a significant number of scientists are sounding the alarm," Mark Fergusson, CEO of Down to Earth Organic & Natural, said in an essay posted on his organization's website. "They say genetic engineering poses risks that scientists simply do not know enough to identify."

Fergusson encouraged the public to choose foods with the organic seal, certifying that GMOs were not used in production.

GMO advocates argue that reputable scientific data evidencing health risks of GMO technology has yet to be produced.

The industry's comments to the National Academy of Sciences on Sept. 9, 2015, for example, cited several studies on the safety of GMO crops, including a 2011 summary report by the European Commission covering a decade of publicly funded research, 130 research projects and 500 research groups concluding "there is no scientific evidence of higher risks of GE crops for food and feed safety, or to the environment."

The environmental benefits of GMO crops, however, are well documented, Markwart said.

When beets were raised conventionally, Markwart said herbicides applied about four times per year to control weeds stymied crop development, essentially taking a month of growth off of the final yield. Glyphosate applications in GMO beets don't set development back whatsoever, enabling farmers to produce more with fewer farming inputs.

Furthermore, GMO beets don't require hand weeding and mechanical cultivation between rows, saving farmers on labor costs and avoiding soil disturbance, which dries out soil and releases greenhouse gases.

The sugar beet industry points to a 2002 study by the National Center for Food and Agriculture Policy evaluating eight of the most commonly used herbicides, finding glyphosate posed the least potential risk. Furthermore, glyphosate binds tightly to the soil and is less likely to contaminate groundwater, according to the industry's literature.

According to USDA data, sugar beet yields increased by 19% with glyphosate-resistant seed from 2008 through 2015 compared with the conventional average. The percentage of sugar in each beet also increased dramatically.

Brad Griff, executive director of the Idaho Sugarbeet Growers Association, said the Gem State's farmers have increased their yields by roughly 10 tons per acre on average since the implementation of GMO sugar beets.

"Before the GE sugar beet we never had reached 18% sugar. Now for three of the last six years we've been at or above 18% sugar," Griff added. "That's all been accomplished while reducing pesticide use by 85% and reducing fuel use by 60%."

In its Agriculture Innovation Agenda, USDA asked farmers of various commodities to plan strategies to increase their output by 40% while cutting their environmental impacts in half. The sugar beet industry submitted comments toward that effort focusing largely on achieving the goals through improved genetics.

Looking ahead, Markwart anticipates sugar beet seed engineered with multiple-trait tolerance to three herbicides glyphosate, dicamba and glufosinate should be released by 2026. He explained the new seed should help farmers avoid the onset of glyphosate-resistant weeds by enabling them to use multiple modes of action.

The industry also sees great promise in gene editing, which allows crop breeders to silence or amplify existing traits in a plant's genetics rather than introducing desirable foreign traits.

Herndon believes sustainability should be viewed as a "three-legged stool" factoring in social, economic and environmental costs. He said farmers are the lifeblood of rural economies and have a social contract to help keep their rural communities afloat. While it's important that they continually push the envelope to reduce their impacts on the environment, Herndon said farmers must also eke out a profit.

Markwart added, "We used to have hand labor. No one is going to go back and do that again. We have made major advances in efficiencies with this technology."

Excerpt from:
Sugar beet industry flips narrative on GMO crops - Idaho State Journal

Read More...

Lesaffre and Recombia Biosciences apply gene editing technology in fermented ingredients production – FoodIngredientsFirst

October 31st, 2020 5:52 pm

30 Oct 2020 --- French yeast manufacturer Lesaffre and Recombia Biosciences have partnered to advance a gene editing technology for the sustainable production of fermented ingredients.

Using Recombias proprietary gene editing technologies, the partnership aims to generate thousands of new yeast strains while optimizing the production of biosourced ingredients.

We see tremendous potential to leverage our expertise in genome editing and synthetic biology to develop new and innovative fermentation solutions and products, says Dr. Justin Smith, CEO of Recombia Biosciences.

Click to EnlargeThe partnership signals Lesaffres entry into the world of Synthetic Biology, which the company notes is considered to be a major biotechnological opportunity of this decade.Recombia Biosciences was founded by three Stanford University researchers in 2019 as a spin-off from the Stanford Genome Technology Center (SGTC), in the US.

Its technologies are based upon techniques that increase the efficiency of genome editing and enable engineering of yeast at very high throughput.

The technology has broad utility and can be readily applied also to the development of non-genetically modified organisms, adds Carmen Arruda, R&I manager at Lesaffre.

With Recombia, Lesaffre can now explore a larger space of metabolic engineering hypotheses, develop prototype organisms at a faster pace, accelerate the design of appropriate selections and screenings of strains generated by classical breeding methods. Were excited to see what the future holds.

Entry into synthetic biologyThe partnership signals Lesaffres entry into the world of Synthetic Biology, which the company notes is considered to be a major biotechnological opportunity of this decade.

This kind of partnership exemplifies an innovative way that industry can support and foster progress in Biotechnology, says Antoine Baule, CEO of Lesaffre.

Through collaborations with scientists and entrepreneurs, we will be able to find new solutions, which will be beneficial for the future, especially in health or in environment protection.

Recombia is exclusively licensing four genome engineering technologies from Stanford University for their work.

Bridging industry with academiaWhile precision genome editing has certainly advanced recently, there are still challenges, especially in making many genetic changes in parallel, notes Dr. Bob St.Onge, COO and co-founder of Recombia Biosciences.

Recombias technologies enable industrial yeast strain engineering by dramatically increasing the efficiency of high-throughput genome editing, he remarks.

Click to EnlargeWhile precision genome editing has certainly advanced recently, there are still challenges ahead.

St.Onge and Smith co-founded the company with Professor Lars Steinmetz. The team has had a significant working relationship at the Stanford Genome Technology Center (SGTC).

Im very excited to see the technologies we developed in academia applied in the industrial sector, comments Steinmetz.

The Genome Technology Center has a long history of genomics technology development. Im confident Recombia will continue in the tradition of the other successful companies that have spun out of the SGTC.

Unlocking the genome for new ingredientsGenomic research is widely applicable across food-tech applications. For instance, this type of analysis is employed to map the chemical fingerprint of chocolate, using the genes of the tree that cacao pods are harvested from.

Also in this space, seed breeding specialist Equinom is leveraging its advanced breeding techniques to promote agricultural biodiversity. The company upholds its pivotal position in inducing better crop resilience and increased yield.

Meanwhile, a genomic study comparing historic and modern wheat varieties recently revealed an increase in dietary fiber and a decrease in acrylamide, indicating that white bread is not as unhealthy as it has often been portrayed.

Edited by Benjamin Ferrer

To contact our editorial team please email us at editorial@cnsmedia.com

If you found this article valuable, you may wish to receive our newsletters. Subscribe now to receive the latest news directly into your inbox.

Go here to see the original:
Lesaffre and Recombia Biosciences apply gene editing technology in fermented ingredients production - FoodIngredientsFirst

Read More...

Polymerase Chain Reaction (PCR) Market expanding at a considerable CAGR from 2018 to 2026 – The Think Curiouser

October 31st, 2020 5:52 pm

Transparency Market Research (TMR)has published a new report titled,Polymerase Chain Reaction (PCR) Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026.According to the report, theglobal PCR marketis projected to reach over US$ 7.0 Bn by 2026 expanding at a considerable CAGR from 2018 to 2026. North America is expected to dominate the global PCR market during the forecast period, due to high adoption of technologically advanced molecular diagnostic products, growing incidence of infectious diseases, rising prevalence of various types of cancer, growing trend of self-diagnosis of diseases, and affordability of high-cost testing processes for people in the region.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=830

Reagents Segment to Dominate the Global PCR Market

The report offers detailed segmentation of the global PCR market based on product and end-user. In terms of product, the market has been segmented into instruments, reagents, and consumables. The reagents segment held the leading market share in the year 2017 and is expected to expand at the highest CAGR during the forecast period. This is attributable to high consumption of reagents for the PCR technique. Introduction of advanced reagents specific to the type of test is expected to boost the global demand for PCR reagents in the near future. PCR reagents include template DNA, PCR primers and probes, dNTPs, PCR buffers, enzymes, and master mixes. PCR consumables mostly include PCR tubes, plates, and other accessories required to conduct PCR reactions. The instruments segment has been sub-categorized into standard PCR systems, RT PCR systems, and digital PCR systems. Among these, the digital PCR systems sub-segment is expected to witness growth at a significantly rapid pace during the forecast period. This is attributable to advantages of digital PCR systems such as precision, sensitivity, accuracy, reproducibility, direct quantification and multiplexing, and speed of the analysis.

Request for Analysis of COVID19 Impact on Polymerase Chain Reaction (PCR) Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=830

Pharmaceutical & Biotechnology Industry Segment Held a Major Share of the Global PCR Market in 2017

The PCR technique has been found to be useful in pharmaceutical and biotechnology research activities as well as microbial quality testing. The technique is also applied in genetic engineering. Genetic engineering is the key driver for the global PCR market. It is used to identify genes related to certain phenotypes includinggenetic disorders. Regular testing of the microbial load of raw materials and finished products is an important process in the pharmaceutical & biotechnology industry. Sophisticated analytical methods such as polymerase chain reaction (PCR) have been widely applied for quality control analysis in the pharmaceutical sector.

Market in Asia Pacific to Expand at a High CAGR

Molecular diagnosis has revolutionized the modern diagnosis technology. PCR has become a method of choice in early and accurate detection of diseases. Expansion by leading manufacturers of PCR products in the Asia Pacific region by strengthening of the distribution network and new product launches in developing countries of Asia Pacific are key factors likely to drive the PCR market in the region during the forecast period. Moreover, rise in the incidence of cancer and infectious diseases has resulted in increase in the demand for use of the PCR technique in clinical diagnosis of these diseases in Asia Pacific. For instance, according to the Korea Central Cancer Registry published in 2016, there were 217,057 cancer cases in South Korea in 2014. Moreover, in 2016, the WHO estimated that the Asia Pacific region has the second-highest number (i.e. 5.1 million) of people living with HIV across the world. Thus, Asia Pacific is expected to be the most lucrative market for PCR by 2026.

Buy Polymerase Chain Reaction (PCR) Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=830&ltype=S

Competition Landscape

Major players operating in the global PCR market are Bio-Rad Laboratories, Inc., QIAGEN N.V., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc. Becton, Dickinson and Company, Abbott, Siemens Healthcare GmbH (Siemens AG), bioMrieux SA, Danaher Corporation, and Agilent Technologies. Key players are expanding their product portfolio through mergers and acquisitions and partnerships and collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read more:
Polymerase Chain Reaction (PCR) Market expanding at a considerable CAGR from 2018 to 2026 - The Think Curiouser

Read More...

Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel – BioSpace

October 31st, 2020 5:52 pm

SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. Dr. Hasan Jafri, Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled "Direct Antivirals and Other Agents Against SARS-CoV2 Virus."

Panel: Direct Antivirals and Other Agents Against SARS-CoV2 VirusDate: Wednesday, October 28, 2020Time: 10:30AM-11:50AM ET

Dr. Jafri will present a summary of the Company's recently published preclinical data of its COVID-19 inhaled mAb (AR-711). He will address the preclinical performance of AR-711, the advantages of direct lung delivery using nebulized aerosols, and the COVID-19 clinical program.

About AR-711

AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients. AR-711 exhibits high affinity for SARS-CoV-2 spike protein, approximately 10-fold or higher than mAb candidates currently in late stage clinical testing. AR-711 was previously shown to be effective in prophylactic as well as therapeutic treatment modes in a SARS-CoV-2 viral challenge study. AR-711 is currently being developed as an inhaled, self-administered treatment for non-hospitalized patients suffering from mild to moderate COVID-19. AR-711 is also one the two mAbs in the company's AR-701 mAb cocktail, which is a separate program being developed as an intravenous treatment of moderate to severe, hospitalized COVID-19 patients.

About Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary PEXTM and MabIgX technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.

The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company's pipeline is highlighted below:

Aridis' Pipeline

AR-301 (VAP). AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive Staphylococcus aureus (S. aureus) alpha-toxin in VAP patients.

AR-101 (HAP). AR-101 is a fully human immunoglobulin M, or IgM, mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa (P. aeruginosa) liposaccharides serotype O11, which accounts for approximately 22% of all P. aeruginosa hospital acquired pneumonia cases worldwide.

AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients. This program is currently in a Phase 1/2a clinical study in healthy volunteers and CF patients.

AR-401 (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative Acinetobacter baumannii.

AR-701 (COVID-19). AR-701 is a cocktail of fully human mAbs discovered from convalescent COVID-19 patients that are directed at multiple envelope proteins of the SARS-CoV-2 virus.

AR-711 (COVID-19). AR-711 is an in-licensed mAb that is directed against the receptor binding domain of the SARS-Cov 2 virus. The agent has the potential to be delivered both intravenously and by inhalation using a nebulizer.

AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb out-licensed preclinical program aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).

For additional information on Aridis Pharmaceuticals, please visit https://aridispharma.com/.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Aridis' expectations, strategy, plans or intentions. These forward-looking statements are based on Aridis' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the need for additional financing, the timing of regulatory submissions, Aridis' ability to obtain and maintain regulatory approval of its existing product candidates and any other product candidates it may develop, approvals for clinical trials may be delayed or withheld by regulatory agencies, risks relating to the timing and costs of clinical trials, risks associated with obtaining funding from third parties, management and employee operations and execution risks, loss of key personnel, competition, risks related to market acceptance of products, intellectual property risks, risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses, risks associated with the uncertainty of future financial results, Aridis' ability to attract collaborators and partners and risks associated with Aridis' reliance on third party organizations. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Aridis' 10-K for the year ended December 31, 2019 and Aridis' other filings made with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and Aridis does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Contact:

Investor RelationsJason WongBlueprint Life Science Groupjwong@bplifescience.com(415) 375-3340 Ext. 4

SOURCE Aridis Pharmaceuticals, Inc.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aridis-pharmaceuticals-to-present-at-the-roth-capital-partners-2020-medtech-innovation-forum-on-a-covid-19-panel-301160211.html

SOURCE Aridis Pharmaceuticals, Inc.

Company Codes: NASDAQ-NMS:ARDS

Read the original post:
Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel - BioSpace

Read More...

Aviceda Therapeutics Announces Formation of Scientific Advisory Board – BioSpace

October 31st, 2020 5:52 pm

Oct. 27, 2020 12:00 UTC

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Aviceda Therapeutics, a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing the members of its Scientific Advisory Board who will help shape ongoing development efforts.

The Aviceda Scientific Advisory Board includes Pamela Stanley, PhD; Ajit Varki, MD; Christopher Scott, PhD; Geert-Jan Boons, PhD; Salem Chouaib, PhD; and Peng Wu, PhD.

Aviceda has assembled an extraordinary multi-disciplinary team of world-class scientists and renowned researchers to join our efforts in developing the next generation of glyco-immune therapeutics for the treatment of immune-dysfunction conditions, said Mohamed A. Genead, MD, Founder, CEO & President of Aviceda Therapeutics. Each individual offers a fresh perspective and unique strategic acumen that complements and strengthens the insights of our in-house leadership development team.

Prof. Scott, Aviceda Scientific Co-Founder, is Director of the Patrick G Johnston Centre for Cancer Research and Cell Biology at Queens University Belfast. He is internationally renowned for his work in development of novel approaches in the field of antibody and nanomedicine-based therapies for the treatment of cancer and other conditions. Prof. Scott has a background in both the pharmaceutical industry and academia and was a founding scientist of Fusion Antibodies Plc. Research in his laboratory is funded by agencies such as Medical Research Council, UK charities and various industrial sources. He also held a Royal Society Industrial Fellowship with GSK from 2012 to 2015 and won the Vice Chancellors Prize for Innovation in 2015 with his groups work on developing a novel Siglec targeting nanomedicine for the treatment of sepsis and other inflammatory conditions.

The novelty of Avicedas platform technology is its potential to affect immune responses associated with a wide range of disease states, many of which are currently unmet or underserved needs. I look forward to the continued development of Avicedas core technology and moving forward to clinical trials that will pave the way for truly disruptive therapeutic strategies to enter the clinic that will significantly impact and improve patients lives in the not-too-distant future, said Prof. Scott.

Avicedas Scientific advisory chairwoman, Prof. Stanley, is the Horace W. Goldsmith Foundation Chair; Professor, Department of Cell Biology; and Associate Director for Laboratory Research of the Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York. She obtained a doctorate degree from the University of Melbourne, Australia, for studies of influenza virus, and was subsequently a postdoctoral fellow of the Medical Research Council of Canada in the laboratory of Louis Siminovitch, University of Toronto, where she studied somatic cell genetics. Prof. Stanleys laboratory is focused on identifying roles for mammalian glycans in development, cancer and Notch signaling. Among her many varied contributions, Prof. Stanleys laboratory has isolated a large panel of Chinese hamster ovary (CHO) glycosylation mutants; characterized them at the biochemical, structural and genetic levels; and used them to identify new aspects of glycan synthesis and functions. She serves on the editorial boards of Scientific Reports, Glycobiology and FASEB Bio Advances; she is an editor of the textbook Essentials of Glycobiology; and her laboratory is the recipient of grants from the National Institutes of Health. Prof. Stanley has received numerous awards, including a MERIT award from the National Institutes of Health, an American Cancer Society Faculty Research Award, the Karl Meyer Award from the Society for Glycobiology (2003) and the International Glycoconjugate Organization (IGO) Award (2003).

Working with Aviceda represents a unique opportunity to contribute to science at the cutting edge. Its pipeline contains a broad range of candidates that represents numerous first-in-class opportunities, said Prof. Stanley.

Prof. Varki is currently a distinguished professor of medicine and cellular and molecular medicine, Co-director of the Glycobiology Research and Training Center and Executive Co-director for the UCSD/Salk Center for Academic Research and Training in Anthropogeny at the University of California, San Diego; and an Adjunct Professor at the Salk Institute for Biological Studies. Dr. Varki is also the executive editor of the textbook Essentials of Glycobiology. He received basic training in physiology, medicine, biology and biochemistry at the Christian Medical College, Vellore, The University of Nebraska, and Washington University in St. Louis, as well as formal training and certification in internal medicine, hematology and oncology. Dr. Varki is the recipient of numerous awards and recognitions, including election to the American Academy of Arts and Sciences and the US National Academy of Medicine, a MERIT award from the National Institutes of Health, an American Cancer Society Faculty Research Award, the Karl Meyer Award from the Society for Glycobiology and the International Glycoconjugate Organization (IGO) Award (2007).

The Aviceda team is already building on the foundational work in the emerging field of glycobiology to develop potential therapeutics and interventional strategies. Their work could be critically important for growing the understanding of how glycobiology and glycochemistry are applicable to immunology, and more broadly, to the field of drug and therapeutic development, said Prof. Varki.

Prof. Boons is a Distinguished Professor in Biochemical Sciences at the Department of Chemistry and the Complex Carbohydrate Research Center (CCRC) of the University of Georgia (USA) and Professor and Chair of the Department of Medicinal and Biological Chemistry of Utrecht University (The Netherlands). Prof. Boons directs a research program focused on the synthesis and biological functions of carbohydrates and glycoconjugates. The diversity of topics to which his group has significantly contributed includes the development of new and better methods for synthesizing exceptionally complex carbohydrates and glycoconjugates. Highlights of his research include contributions to the understanding of immunological properties of complex oligosaccharides and glycoconjugates at the molecular level, which is being used in the development of three-component vaccine candidates for many types of epithelial cancer; development of convergent strategies for complex oligosaccharide assembly, which make it possible to synthesize large collections of compounds with a minimal effort for structure activity relationship studies; and creation of a next generation glycan microarray that can probe the importance of glycan complexity for biological recognition, which in turn led to identification of glycan ligands for various glycan binding proteins that are being further developed as glycomimetics for drug development for various diseases. Among others, Prof. Boons has received the Creativity in Carbohydrate Science Award by the European Carbohydrate Association (2003), the Horace Isbell Award by the American Chemical Society (ACS) (2004), the Roy L. Whistler International Award in Carbohydrate

Chemistry by the International Carbohydrate Organization (2014), the Hudson Award (2015) and the Cope Mid-Career Scholar Award from ACS (2016).

Aviceda is leading the field of glycoimmunology in exciting new directions. I look forward to working with the company as it pursues multiple lines of development efforts that will someday transform the way immune-inflammatory conditions are treated in the clinic, said Prof. Boons.

Prof. Chouaib is the Director of Research, Institute Gustave Roussy, Paris, where he is active in research in tumor biology. Previously, Prof. Chouaib worked at the French National Institute of Health and Biomedical Research (INSERM) where he led a research unit focused on the investigation of the functional cross talk between cytotoxic cells and tumor targets in the context of tumor microenvironment complexity and plasticity. His research was directed at the transfer of fundamental concepts in clinical application in the field of cancer vaccines and cancer immunotherapy. Prof. Chouaib is a member of the American Association of Immunologists, New York Academy of Sciences, French Society of Immunologists, International Cytokine Society, American Association for Cancer Research, International Society for Biological Therapy of Cancer and American Association of Biological Chemistry. He was awarded the cancer research prize of the French ligue against cancer in 1992 and in 2004 the presidential prize in biotechnology. He was awarded for translational research and scientific excellency by INSERM. His research has resulted in more than 310 scientific articles and several reviews in the field of human immunology, tumor biology and cancer immunotherapy; he has also been an editor for several textbooks.

Dr. Wu is an Associate Professor in the Department of Molecular Medicine at Scripps Research. The current research in the Wu laboratory integrates synthetic chemistry with glycobiology to explore the relevance of protein glycosylation in human disease and cancer immunotherapy. In 2018, Dr. Wu developed a platform to construct antibody-cell conjugates for cancer immunotherapy, which does not require genetic engineering. Previously, while working as a postdoctoral fellow in the group of Professor Carolyn R. Bertozzi at the University of California, Berkeley, Dr. Wu developed an aldehyde-tag (SMARTag) based technology for site-specific labeling of monoclonal antibodies, which served as the foundation for Redwood Biosciences Inc., a biotech company co-founded by Bertozzi. In 2014, Redwood Bioscience Inc. and the SMARTag Antibody-Drug Conjugate technology platform was acquired by Catalent Pharma Solutions.

About Aviceda Therapeutics

Founded in 2018 and based in Cambridge, Massachusetts, Aviceda Therapeutics is a late-stage, pre-clinical biotechnology company with a mission to develop the next generation of glyco-immune therapeutics (GITs) utilizing a proprietary technology platform to modulate the innate immune system and chronic, non-resolving inflammation. Aviceda has assembled a world-class, cross-disciplinary team of recognized scientists, clinicians and drug developers to tackle devastating ocular and systemic degenerative, fibrotic, oncologic and immuno-inflammatory diseases. At Aviceda, we exploit a unique family of receptors found expressed on all innate immune cells and their associated glycobiological interactions to develop transformative medicines. Combining the power of our biology with our innovative cell-based high-throughput screening platform and proprietary nanoparticle technology, we can modulate the innate immune response specifically and profoundly. Aviceda is developing a pipeline of GITs that are delivered via biodegradable nanoparticles and which safely and effectively target numerous immune-inflammatory conditions. Avicedas lead ophthalmic optimized nanoparticle, as an intravitreal formulation, AVD-104, is being developed to target various immune system responses that contribute to pathology associated with age-related macular degeneration (AMD).

View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005101/en/

Read this article:
Aviceda Therapeutics Announces Formation of Scientific Advisory Board - BioSpace

Read More...

Page 315«..1020..314315316317..320330..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick